To date, gemtuzumab ozogamicin (GO), an anti-CD33 ADC, was approved for treatment of acute myeloid leukemia (AML) by the Food and Drug Administration (FDA) in 2000 (2, 9), but to date no ADC has been approved for CMML therapy. The gene discussed is CD33; the disease is acute myeloid leukemia.